RxDoctor Payments Data

Deepak Suresh, MD

Hospitalist · Newport Beach, CANPI 1326306580

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (51.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Portola Pharmaceuticals, LLC accounts for 61.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $5,041 and has fallen 80.0% since, to $1,008 in 2024. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,771in general payments, 2019–2025

Across 72 payments — averaging $107.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Portola Pharmaceuticals, LLC$5K
  • Johnson & Johnson$2K
  • Gilead$239
  • Nabriva Therapeutics, PLC$209
  • Kestra Medical Technology Services, Inc.$162
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$125
  • plus $439 from 4 others

What the payments were for

  • Speaking & faculty fees$4,00051%
  • Travel & lodging$5347%
  • Food & beverage$3,23642%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,771 in reported general payments places this provider in the 95th percentile of 2,469 hospitalist providers in California.

See all hospitalist providers in California

Medicare billing

Part B allowed, 2024
$137,515
Medicare patients
502
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$9,349
Atorvastatin Calcium15$85
Cefdinir11$84
Prednisone13$65
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$63
Furosemide12$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$9,34912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,469 hospitalist providers in California.

Other hospitalist in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →